ATE457999T1 - Bifunktionelle proteinanker - Google Patents

Bifunktionelle proteinanker

Info

Publication number
ATE457999T1
ATE457999T1 AT06783852T AT06783852T ATE457999T1 AT E457999 T1 ATE457999 T1 AT E457999T1 AT 06783852 T AT06783852 T AT 06783852T AT 06783852 T AT06783852 T AT 06783852T AT E457999 T1 ATE457999 T1 AT E457999T1
Authority
AT
Austria
Prior art keywords
antigen
immunogenic carrier
polypeptide
interest
bifunctional protein
Prior art date
Application number
AT06783852T
Other languages
English (en)
Inventor
Cornelis Leenhouts
Rosmalen Maarten Van
Tjibbe Bosma
Original Assignee
Applied Nanosystems Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Nanosystems Bv filed Critical Applied Nanosystems Bv
Application granted granted Critical
Publication of ATE457999T1 publication Critical patent/ATE457999T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/335—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Lactobacillus (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6056—Antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/622—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier non-covalent binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/705—Fusion polypeptide containing domain for protein-protein interaction containing a protein-A fusion

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT06783852T 2005-07-20 2006-07-20 Bifunktionelle proteinanker ATE457999T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05076680A EP1746103A1 (de) 2005-07-20 2005-07-20 Bifunktionelle Protein-Anker
PCT/NL2006/000382 WO2007011216A2 (en) 2005-07-20 2006-07-20 Bifunctional protein anchors

Publications (1)

Publication Number Publication Date
ATE457999T1 true ATE457999T1 (de) 2010-03-15

Family

ID=35005648

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06783852T ATE457999T1 (de) 2005-07-20 2006-07-20 Bifunktionelle proteinanker

Country Status (10)

Country Link
US (3) US9011870B2 (de)
EP (2) EP1746103A1 (de)
CN (1) CN101268095B (de)
AT (1) ATE457999T1 (de)
AU (1) AU2006270565B2 (de)
CA (1) CA2615738C (de)
DE (1) DE602006012328D1 (de)
DK (1) DK1910408T3 (de)
NZ (1) NZ565271A (de)
WO (1) WO2007011216A2 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1746103A1 (de) * 2005-07-20 2007-01-24 Applied NanoSystems B.V. Bifunktionelle Protein-Anker
EP2168987A1 (de) * 2008-09-22 2010-03-31 Mucosis B.V. Multifunktionelles Linker-Protein enthaltend einen anti-Hämagglutinin-Antikörper, ein konserviertes Influenza-Antigen und eine immunostimulierende Träger-Bindungsdomäne
US20130004547A1 (en) * 2009-07-13 2013-01-03 Vaxgene Corporation Oral vaccines produced and administered using edible micro-organisms including lactic acid bacterial strains
EP2308506A1 (de) 2009-10-02 2011-04-13 Mucosis B.V. Intranasale Adjuvansimpfstoffformulierungen
WO2011044576A2 (en) * 2009-10-09 2011-04-14 Children's Medical Center Corporation Selectively disrupted whole-cell vaccine
CN102796757A (zh) * 2012-06-28 2012-11-28 郑州大学 在乳酸乳球菌表面展示表达幽门螺杆菌蛋白的载体及其制备方法和应用
CN102796756A (zh) * 2012-06-28 2012-11-28 郑州大学 可在乳酸乳球菌表面展示表达异源基因的载体及其制备方法与应用
CN107417773B (zh) * 2016-05-30 2020-09-08 国盛生化股份有限公司 黏合细胞壁之胜肽
CN107033224B (zh) * 2017-01-26 2018-11-02 江苏省农业科学院 一种口蹄疫病毒灭活抗原纯化浓缩方法
CN106589077B (zh) * 2017-01-26 2020-07-10 江苏省农业科学院 一种猪圆环病毒2型抗原纯化浓缩方法
CN107899017B (zh) * 2017-08-16 2021-06-08 祝康生物科技有限公司 一种天然生物纳米靶向药物复合体材料及其制备方法和应用
CN107460173B (zh) * 2017-09-08 2020-09-22 江苏省农业科学院 一种纯化猪流行性腹泻病毒、猪繁殖与呼吸综合征病毒或禽流感病毒的方法
CN109180818A (zh) * 2018-08-08 2019-01-11 天津大学 一种利用gem纯化包涵体的方法
CN109022395A (zh) * 2018-08-08 2018-12-18 天津大学 一种纯化固定化重组α-淀粉酶的方法
CN110628746A (zh) * 2019-09-10 2019-12-31 天津大学 制备BEM用于纯化固定化带有AcmA重组蛋白的方法
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5151350A (en) 1982-10-27 1992-09-29 Repligen Corporation Cloned genes encoding recombinant protein a
EP0682710B1 (de) * 1993-02-10 2003-10-29 Unilever Plc Isolierungsverfahren verwendend immobilisierte proteine mit spezifischen bindungskapazitäten
EP0916726A1 (de) * 1997-11-13 1999-05-19 Rijksuniversiteit te Groningen Befestigungs-Substanzen an Mikroorganismen
EP1192242B1 (de) * 1999-06-25 2010-05-05 Wyeth Holdings Corporation Herstellung der lipid-modifizierten form des peptidoglykan-assoziierten lipoproteins aus gram-negativen bakterien
AU2001280836A1 (en) 2000-07-31 2002-02-13 Meditech Pharmaceuticals, Inc. Compounds, compositions, and methods for the treatment of plant bacterial and fungal infections
JP4651213B2 (ja) 2001-03-27 2011-03-16 株式会社グライコメディクス インフルエンザウイルス・ヘマグルチニン結合性ペプチド
NZ530527A (en) * 2001-06-11 2006-06-30 Applied Nanosystems B Methods for binding AcmA-type protein anchor fusions to cell-wall material of micro-organisms
EP1477802A1 (de) * 2003-05-16 2004-11-17 Erasmus Universiteit Rotterdam Verfahren zur Auswahl und zum Herstellung von Impfstoffkomponenten, und deren Verwendung in Impfstoffen
EP1634076A2 (de) 2003-06-10 2006-03-15 CatchMabs B.V. Bindungs peptide: methoden zur herstellung und verwendung
EP1746103A1 (de) * 2005-07-20 2007-01-24 Applied NanoSystems B.V. Bifunktionelle Protein-Anker
EP2168987A1 (de) * 2008-09-22 2010-03-31 Mucosis B.V. Multifunktionelles Linker-Protein enthaltend einen anti-Hämagglutinin-Antikörper, ein konserviertes Influenza-Antigen und eine immunostimulierende Träger-Bindungsdomäne
EP2308506A1 (de) * 2009-10-02 2011-04-13 Mucosis B.V. Intranasale Adjuvansimpfstoffformulierungen
WO2012128628A1 (en) * 2011-03-22 2012-09-27 Mucosis B.V. Immunogenic compositions in particulate form and methods for producing the same

Also Published As

Publication number Publication date
NZ565271A (en) 2010-07-30
US9011870B2 (en) 2015-04-21
US20160136294A1 (en) 2016-05-19
WO2007011216A2 (en) 2007-01-25
CA2615738A1 (en) 2007-01-25
DE602006012328D1 (de) 2010-04-01
AU2006270565B2 (en) 2011-05-12
WO2007011216A3 (en) 2007-03-08
US20090263414A1 (en) 2009-10-22
CA2615738C (en) 2013-06-04
EP1910408A2 (de) 2008-04-16
CN101268095A (zh) 2008-09-17
EP1910408B1 (de) 2010-02-17
US20150196659A1 (en) 2015-07-16
EP1746103A1 (de) 2007-01-24
DK1910408T3 (da) 2010-06-07
AU2006270565A1 (en) 2007-01-25
CN101268095B (zh) 2013-01-09

Similar Documents

Publication Publication Date Title
DK1910408T3 (da) Bifunktionelle proteinankre
HRP20201770T1 (hr) Nova imunoterapija protiv raznih vrsta karcinoma, uključujući gastrointestinalni karcinom i gastrični karcinom
CY1107390T1 (el) Εμβολιο εναντι αντιγονων απο βακτηριδια
WO2002080851A3 (en) Chimeric vaccines
WO2008021076A3 (en) Protein matrix vaccines and methods of making and administering such vaccines
WO2006081007A3 (en) Use of flagellin in tumor immunotherapy
WO2008040362A3 (en) Generation of a cancer-specific immune response toward muc1 and cancer specific muc1 antibodies
WO2004075829A3 (en) Adjuvanted influenza vaccine
HK1135431A1 (en) Therapeutic applications of activation of human antigen-presenting cells through dectin-1
TR200103333T2 (tr) Dayanıklığı ve biyolojik uygunluğu iyileştiren yardımcı ilaç (SBA)
NO20083891L (no) Anti-5T4 antistoffer og anvendelser derav
DK2142570T3 (da) Anti-EpCam-antistof og anvendelser deraf
BRPI0411854A (pt) veìculos protéicos para vacinas
EP2457928A3 (de) Monoklonale humane tumorspezifische Antikörper
WO2006083301A3 (en) Immunogenic compositions comprising hmgb1 polypeptides
WO2006110728A3 (en) Immunogenic cmv tegument aggregates
EA201100268A1 (ru) Вакцина
WO2005105139A3 (en) Mage-3 and ny-eso-1 based polyvalent vaccine for cancer immunotherapy
WO2006083792A3 (en) Novel polypeptide ligands for toll-like receptor 2 (tlr2)
WO2007008918A3 (en) Virus vaccines comprising envelope-bound immunomodulatory proteins and methods of use thereof
ATE370745T1 (de) Verbesserte polysaccharid- und glykokonjugat- vakzine
WO2009070507A3 (en) Anaplasma phagocytophilum (aph) antigens and antibodies specific for anaplasma
WO2005007673A3 (en) Immunogenic peptides
ATE551069T1 (de) Mucin-fusionspolypeptid-vakzine, zusammensetzungen und ihre verwendung
WO2006117538A3 (en) Assays for diagnosis of tuberculosis and uses thereof

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1910408

Country of ref document: EP